Company & Sponsor Intelligence
Supernus Pharmaceuticals, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed2
Countries2
Therapeutic footprint
adhdepilepsy
Indexed studies
NCT05518578Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT00918424Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects
epilepsy · United StatesAPPROVED_FOR_MARKETING
epilepsy · United StatesAPPROVED_FOR_MARKETING
NCT03156439Bioavailability, Safety, and Tolerability of BIS-001 ER
epilepsy · AustraliaPHASE1
epilepsy · AustraliaPHASE1
NCT02633527Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
adhd · United StatesPHASE2
adhd · United StatesPHASE2
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →